Valuation: Compass Therapeutics, Inc.

Market Cap 150M 134M 124M 112M 211M 14.25B 215M 1.49B 585M 7.45B 564M 552M 23.78B P/E 2026 *
-1.68x
P/E 2027 * -1.49x
Enterprise Value 373K 332K 308K 279K 525K 35.37M 533K 3.7M 1.45M 18.51M 1.4M 1.37M 59.06M EV / Sales 2026 *
-
EV / Sales 2027 * 2.67x
Free-Float
87.53%
Yield 2026 *
-
Yield 2027 * -
1 day+1.68%
1 week-0.19%
Current month-17.75%
1 month-53.00%
3 months-57.65%
6 months-84.20%
Current year-84.07%
1 week 0.82
Extreme 0.8217
0.91
1 month 0.82
Extreme 0.8217
1.88
Current year 0.82
Extreme 0.8217
6.88
1 year 0.82
Extreme 0.8217
6.88
3 years 0.76
Extreme 0.765
6.88
5 years 0.76
Extreme 0.765
6.88
10 years 0.76
Extreme 0.765
11
Manager TitleAgeSince
Chief Executive Officer 65 2024-05-27
Director of Finance/CFO 54 2024-12-08
Chief Tech/Sci/R&D Officer 50 2025-12-31
Director TitleAgeSince
Director/Board Member 65 2013-12-31
Director/Board Member 64 2014-12-31
Chairman 61 2014-12-31
Date Insider Type Main position Quantity % Market Cap. Importance
10/1/26 Buy

Controller/Auditor

20,000 0.0111%
9/24/26 Buy

Controller/Auditor

2,500 0.0014%
4/29/26 Buy

Controller/Auditor

15,000 0.0083%
Change 5-day change 1-year change 3-year change Capi.($)
+1.68%-0.19%-78.88%-56.80% 150M
+0.79%-6.46%+52.86%+71.34% 65.83B
+1.92%+10.35%+13.02%+87.74% 51.87B
+6.91%+8.57%+6.88%+72.12% 51.2B
+0.93%+3.10%+26.74%+45.77% 43.76B
+2.53%+8.70%+19.11%+129.69% 42.09B
+6.42%+3.12%+259.79%+594.74% 39.04B
-0.40%+9.42%+18.44%+59.06% 34B
+3.84%-4.94%+42.35%+8.92% 25.2B
+2.36%+5.34%+30.98%+26.07% 22.8B
Average +2.73%-0.63%+39.13%+103.87% 37.6B
Weighted average by Cap. +2.81%+0.61%+50.57%+123.53%

Financials

2026 *2027 *
Net sales - 6.51M 5.8M 5.37M 4.87M 9.15M 617M 9.3M 64.46M 25.32M 323M 24.43M 23.92M 1.03B
Net income -93.27M -83.02M -76.94M -69.72M -131M -8.84B -133M -923M -363M -4.62B -350M -343M -14.75B -112M -99.43M -92.16M -83.51M -157M -10.58B -160M -1.11B -434M -5.54B -419M -410M -17.67B
Net Debt -150M -134M -124M -112M -211M -14.21B -214M -1.48B -583M -7.44B -563M -551M -23.72B -133M -118M -110M -99.42M -187M -12.6B -190M -1.32B -517M -6.59B -499M -489M -21.03B
Projected Income Statement - Annual - Compass Therapeutics, Inc.
Logo Compass Therapeutics, Inc.
Compass Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company. The Company is developing proprietary antibody-based therapeutics to treat multiple human diseases. Its pipeline of novel product candidates is designed to target multiple critical biological pathways required for an effective anti-tumor response. Its lead product candidate, tovecimig, is a bispecific antibody targeting Delta-like ligand 4 (DLL4), a ligand of Notch-1, and vascular endothelial growth factor A (VEGF-A). Its second program, CTX-471, is an agonistic antibody targeting a member of the tumor necrosis factor receptor superfamily member 9 (TNFRSF9), also known as CD-137, a co-stimulatory receptor which is mostly expressed on activated, but not on resting T-cells and NK cells. Its third program, CTX-8371, is a bispecific antibody targeting the programmed cell death protein-1 (PD-1), an inhibitory immune checkpoint receptor, and its ligand PD-L1, two validated immune-oncology targets.
Employees
39
Date Price Change Volume
26-10-20 $0.8561 +2.53% 753,938
26-10-19 $0.8350 -2.91% 3,119,040
26-10-16 $0.8600 -4.09% 2,038,934
26-10-15 $0.8967 +2.01% 3,339,175
26-10-14 $0.8790 +2.57% 4,969,084
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
MarketScreener Ratings - Compass Therapeutics, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
0.8350USD
Average target price
5.455USD
Spread / Average Target
+553.24%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Compass Therapeutics, Inc.
  1. Stock Market
  2. Stocks
  3. CMPX Stock